v3.21.2
Warrants
9 Months Ended
Sep. 30, 2021
Warrants  
Warrants

7. Warrants

 

The following is a summary of activity in the number of warrants outstanding to purchase the Company’s common stock for the nine months ended September 30, 2021 (in thousands):

 Summary of Warrant Activity

  

Warrants

Accounted for as:

Equity

  

Warrants

Accounted for as:

Liabilities

     
   May 2018
Warrants
   October 2013
Warrants
   January 2014
Warrants
   Total 
Outstanding, December 31, 2020   84    26    133    243 
Exercised   -    -    -    - 
Granted   -    -    -    - 
Expired   -    -    -    - 
Outstanding, September 30, 2021   84    26    133    243 
Expiration date:   October 27, 2022    October 24, 2023    January 16, 2024      

 

Warrants Classified as Liabilities

 

Liability-classified warrants consist of warrants issued by Biozone Pharmaceuticals, Inc. (“Biozone”), the company’s predecessor, in connection with equity financings in October 2013 and January 2014, which were assumed by the Company in connection with its merger with Biozone in January 2014. Warrants accounted for as liabilities have the potential to be settled in cash or are not indexed to the Company’s own stock.

 

The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the condensed consolidated statement of operations as changes in fair value of derivative liabilities.

 

The fair value of the warrants classified as liabilities is estimated using the Black-Scholes option-pricing model with the following inputs as of September 30, 2021:

 Schedule of Fair Value of Warrants Classified as Liabilities

   October 2013
Warrants
   January 2014
Warrants
 
         
Strike price  $15.00   $15.00 
Expected dividend yield   0.00%   0.00%
Contractual term (years)   2.1    2.3 
Cumulative volatility   130.84%   127.99%
Risk-free rate   0.09%   0.11%
Value per warrants  $0.19   $0.22 
Aggregate value  $5,031   $28,969 

 

The fair value of the warrants classified as liabilities is estimated using the Black-Scholes option-pricing model with the following inputs as of December 31, 2020:

 

   October 2013
Warrants
   January 2014
Warrants
 
         
Strike price  $15.00   $15.00 
Expected dividend yield   0.00%   0.00%
Contractual term (years)   2.8    3.0 
Cumulative volatility   119.18%   116.65%
Risk-free rate   0.16%   0.18%
Value per warrants  $0.36   $0.38 
Aggregate value  $9,406   $51,151 

 

The Company estimates volatility using its own historical stock price volatility. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero-coupon rates in effect at the balance sheet date. The dividend yield used in the pricing model is zero, because the Company has no present intention to pay cash dividends.